Omeros Corporation
Biopharmaceutical company.
Based in WA
🤖
AI Overview
With $1.9M in lobbying spend across 25 quarterly filings, Omeros Corporation is a significant lobbying presence.
$1.9M
Total Lobbying Spend
25
Quarterly Filings
1
Lobbying Firms Used
4
Individual Lobbyists
Spending by Year
| Year | Lobbying Spend |
|---|---|
| 2018 | $300K |
| 2019 | $240K |
| 2020 | $160K |
| 2021 | $240K |
| 2022 | $240K |
| 2023 | $320K |
| 2024 | $320K |
| 2025 | $70K |
Lobbying Firms
THE NICKLES GROUP, LLC
What They Lobby For
- H.R. 1892, Bipartisan Budget Act of 2018 and H.R. 1625, Consolidated Appropriations Act of 2018 and issues related to Medicare payment policy in hospital outpatient and ambulatory surgical center settings. H.R. 4683, a bill to amend title XVIII of the SSA to revise the NTAP period under Medicare inpatient prospective payment system and the pass-through period under the Medicare outpatient PPS.
- H.R. 1892, Bipartisan Budget Act of 2018 and H.R. 1625, Consolidated Appropriations Act of 2018.
- Monitored issues related to prescription drug pricing for outpatient drugs.
- Issues related to opioids.
- Monitored issues related to prescription drug prices; issues related to the Merit-Based Incentive Payment System (MIPS); issues related to the packaging of drugs in the 2019 hospital outpatient proposed rule.
- Monitored issues related to prescription drug prices; issues related to the Merit-Based Incentive Payment System (MIPS); issues related to the packaging of drugs in the 2019 hospital outpatient proposed rule; H.R. 5172, NOPAIN Act and S. 3067, Non-Opioids Prevent Addiction In the Nation Act and issues involving access to patients to non-opioid alternatives.
- Monitored issues related to prescription drug prices; H.R. 5172, NOPAIN Act and S. 3067, Non-Opioids Prevent Addiction In the Nation Act and issues involving access to patients to non-opioid alternatives; issues related to outpatient reimbursement.
- Monitored issues related to prescription drug prices; H.R. 5172, NOPAIN Act and S. 3067, Non-Opioids Prevent Addiction In the Nation Act and issues involving access to patients to non-opioid alternatives; issues related to the 2021 OPPS final rule; monitored issues related to H.R. 133, the Consolidated Appropriations Act of 2021.
- Monitored issues related to prescription drug prices; H.R.3259, Non-Opioids Prevent Addiction In the Nation Act (NOPAIN Act) and issues involving access to patients to non-opioid alternatives; monitored implementation of P.L. 117-2, the American Rescue Plan.
- Monitored issues related to prescription drug prices; S. 586 / H.R.3259, Non-Opioids Prevent Addiction In the Nation Act (NOPAIN Act) and issues involving access to patients to non-opioid alternatives; monitored implementation of P.L. 117-2, the American Rescue Plan.
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Federal Lobbying Statistics 2025
The definitive stats — $15.2B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.